Cyramza ® (ramucirumab) injection

10 mg/mL solution

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Ramucirumab: Approval for Treatment of NSCLC

In the US, ramucirumab, in combination with erlotinib, is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

Detailed Information

On May 29, 2020, the FDA approved ramucirumab, in combination with erlotinib, for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.1

Enclosed Prescribing Information

CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly

Reference

1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Glossary

EGFR = epidermal growth factor receptor

FDA = Food and Drug Administration 

NSCLC = non-small cell lung cancer

Date of Last Review: May 29, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical